Genmab A (GMAB) Total Current Liabilities (2019 - 2026)

Genmab A's Total Current Liabilities history runs 6 years deep, the most recent figure standing at $1.2 billion for Q1 2026.

• Quarterly Total Current Liabilities changed N/A year-over-year to $1.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 billion (changed N/A YoY) and the FY2025 annual result came in at $1.4 billion, up 91.8% from the prior year.
• Total Current Liabilities was $1.2 billion for Q1 2026 at Genmab A, down from $1.4 billion in the prior quarter.
• Across five years, Total Current Liabilities topped out at $1.4 billion in Q4 2025 and bottomed at $368.0 million in Q4 2023.
• A 4-year average of $847.8 million and a median of $742.5 million in 2024 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2024 — Total Current Liabilities surged 102.17% — and 2025, when it soared 91.8%.
• Genmab A's Total Current Liabilities stood at $368.0 million in 2023, then jumped by 102.17% to $744.0 million in 2024, then surged by 91.8% to $1.4 billion in 2025, then dropped by 17.45% to $1.2 billion in 2026.
• Business Quant data shows GMAB's Total Current Liabilities at $1.2 billion in Q1 2026, $1.4 billion in Q4 2025, and $741.0 million in Q3 2025.